DFX Intelligence
Private Equity Intelligence
Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.
The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.
Firms / D•••• A••••••• L••••••
D•••• A••••••• L••••••
D•••• Capital invests in life science, biotech, and medtech companies transforming bold ideas into medical breakthroughs.
Classification
- Class
- Buyout firmconfirmed, confidence 85%
- Basis
- R6: 3 of 3 distinct vehicles are sworn Private Equity Funds; 3 reported gross assets on a filing in 2022 or later
- Size band
- Lower middle marketdefined by: proxy: $0.54bn Private Equity Fund GAV on the Form ADV filed 2024-04-01
Classification history (1)
- Sep 13, 2026Buyout firm (confirmed, 85%, cls-pe-1)R6: 3 of 3 distinct vehicles are sworn Private Equity Funds; 3 reported gross assets on a filing in 2022 or later
Regulatory footprint (Form ADV)
- Adviser type
- exempt reporting adviser
- Form ADV filings
- Mar 31, 2022 to Apr 1, 2024
- RAUM
- unknownregulatory assets under management of the adviser; not dry powder, not a fund size
- PE funds, latest filing
- 3
- PE fund GAV, latest filing
- $541Mreported gross assets (Form ADV), not fund size
- All private fund GAV
- $541Mevery private fund type, latest filing
- 2024 PE fund GAV
- $541Msum over funds typed Private Equity Fund with a 2024 or later as-of date
- PE share of funds, lifetime
- 100%
- Fund type mix
- filed 2024-04-01, latest gav Private Equity Fund $541M, latest counts Private Equity Fund 3, lifetime distinct Private Equity Fund 3
- Employees
- unknown
- Headquarters
- Hong Kong, Hong Kong
- Office address
- 19/F, FUNG HOUSE 19-20 CONNAUGHT ROAD CENTRAL, Hong Kong
- Business phone
- 852-3912-0500
Stated criteria beside observed behaviour
41 observed deals
Stated by the firm
- Sectors
- life sciences
- Geography
- not stated or not yet read
- Revenue
- not stated or not yet read
- EBITDA
- not stated or not yet read
- Enterprise value
- not stated or not yet read
- Equity check
- not stated or not yet read
- Control
- not stated or not yet read
- Thesis
- not stated or not yet read
Observed from deals on record
- roles
- add on 1, unknown 39, platform 1
- period
- to 2025-06-30, from 2025-06-30, undated holdings 40, dated observations 2
- window
- last 2025-06-30, first 2025-06-30
- control
- control 1, unknown 40
- companies
- 41
- geography
- investments
- 41
- seller kinds
- transactions
- 1
- cadence by year
- 2025 add ons 1
- platform add on
- add ons 1, platforms 1, add ons per platform unknown
- sector known for
- 10
- disclosed value usd
- n 0
- sector distribution
- count 7, share 0.171, value healthcare services, examples Curamir, Avenzo, Instylla, Phanes Therapeutics, count 3, share 0.073, value life sciences, examples Intrinsic, Tanvex (TWSE: 6541), AltruBio
- holding period years
- n 0
- repeat counterparties
- subsector distribution
- count 6, share 0.146, value outpatient specialty clinics, examples Curamir, Avenzo, Phanes Therapeutics, Luqa, count 2, share 0.049, value life sciences, examples Tanvex (TWSE: 6541), AltruBio, count 1, share 0.024, value medical diagnostic labs, examples Instylla, count 1, share 0.024, value medical devices, examples Intrinsic
41 companies on the graph (1 transactions); most in healthcare services (7); 1 platforms and 1 add-ons; observed 2025 to 2025
Funds
3 on record
| Fund | Vehicle | Vintage | Reported gross assets (Form ADV), not fund size | GAV by year | Form D sold | Lifecycle |
|---|---|---|---|---|---|---|
| D•••• C•••••• F••• I••• L• ADV: Private Equity Fund | buyout or unlabelled | unknown | $244M as of Apr 1, 2024 | no Form D | Unknown | |
| D•••• C•••••• F••• I•• L••• ADV: Private Equity Fund | buyout or unlabelled | unknown | $203M as of Apr 1, 2024 | no Form D | Unknown | |
| D•••• C•••••• F•••• L••• ADV: Private Equity Fund | buyout or unlabelled | unknown | $92.9M as of Apr 1, 2024 | no Form D | Unknown |
Team
9 current, 1 former
Managing partner (1)
- H•••• L•• C••• · Founder & Managing Partner · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Partner (6)
- C•••••••• Y•• · Shareholder · since Sep 1, 2014 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
- E••• H••••• P•••• · Partner · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- H•••• L•• C••• · Manager Of D•••• C•••••• Gp Iii, Llc · since Dec 1, 2021 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
- L•• C••••• · Managing Director · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- T•• P•••••• P•••• · Partner · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- T•• X••• · Partner · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Principal (1)
- C•• C•••• C••• · Director Of D•••• C•••••• A••••••• L•• (02/2017); Manager Of D•••• C•••••• Gp Iii, Llc (11/2021) · since Feb 1, 2017 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
Associate (1)
- Y••• C••••• P•••• · Associate · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
1 former (kept with end dates)
- M•••••• C•••• · Director Of D•••• C•••••• A••••••• L•• (02/2017); Manager Of D•••• C•••••• Gp Iii, Llc (11/2021) · Feb 1, 2017 to Apr 1, 2024 Inference
Portfolio
41 relationships, 1 platforms, 1 add-ons
Transactions
1 on record
| Date | Type | Target | This firm’s role | Source |
|---|---|---|---|---|
| Jun 30, 2025 | Add-on acquisition | R••• S••••• | Sponsor (derived) | ostialflash.com |
Placement agents, lenders, advisers and co-investors
1 relationships
Placement agents (1)
- V•• A••••••• ••• L•••••• 1 shared · one time · last Jan 1, 2023
LP commitments
0 disclosed
No LP commitment collected yet. An LP edge needs a public disclosure with a quote, such as a pension plan’s report or an announcement naming the LP.
Events
15 most recent
- Jun 1, 2026Rallybio Corporation and A••••• T••••••••• Announce Merger Agreement to Advance Next-Generation O••••••• Therapies and $215 Million Concurrent Private Placement Acquisition or IPO, Financing | June 01, 2026 | Portfolio News
- May 14, 2026I••••••••• Care Appoints Jay Martin as Chief Commercial Officer Personnel / Awards | May 14, 2026 | Portfolio News
- Mar 27, 2026D•••• A••••••• L••••••: Private Equity Funds on Form ADV 3 (2024 extract) -> 0 (roster 2026-09-01)
- Jan 28, 2026T•••••• Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg T••••••••• Financing | January 28, 2026 | Portfolio News
- Nov 10, 2025A•••••• O••••••• Appoints Paul Blanchfield as Chief Executive Officer Personnel / Awards | November 10, 2025 | Portfolio News
- Aug 14, 2025Chuck Alpuche Appointed to President and COO of I••••••••• Care Personnel / Awards | August 14, 2025 | Portfolio News
- Aug 6, 2025C•••••••• P••••••••• Completes Enrollment in Phase 2 CYCLE Trials Evaluating CRD‑750, a Novel PDE9 inhibitor, in Heart Failure Clinical | August 06, 2025 | Portfolio News
- Aug 5, 2025I••••••• Appoints MedTech Leader Sean Boyle as Chief Executive Officer Personnel / Awards | August 05, 2025 | Portfolio News
- Jun 30, 2025V•••• M•••••• Acquires R•••™ S••••• to Advance Peripheral Embolic Protection Acquisition or IPO | June 30, 2025 | Portfolio News
- May 1, 2025E••••••• Appoints Dr. Jai Patel as Chief M•••••• Officer Personnel / Awards | May 01, 2025 | Portfolio News
- Mar 17, 2025Z•••• BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief M•••••• Officer Personnel / Awards | March 17, 2025 | Portfolio News
- Feb 4, 2025R••••• completes patient enrollment in pivotal clinical study of a Novel Treatment for the Prevention of Intrauterine Adhesions, the Juveena® Hydrogel S•••••. Clinical | February 04, 2025 | Portfolio News
- Jan 30, 2025A••••• T•••••••••, formerly known as Exsilio T•••••••••, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer Personnel / Awards | January 30, 2025 | Portfolio News
- Jul 25, 2024I••••••••• Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors Financing | July 25, 2024 | Portfolio News
- Mar 31, 2022D•••• A••••••• L•••••• first filed Form ADV in the extract (ERA)